The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | CK0804, a cord blood-derived cellular therapy, in myelofibrosis with suboptimal ruxolitinib response
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating CK0804, a cord blood-derived cellular therapy, in patients with myelofibrosis (MF) and suboptimal response to ruxolitinib. Preliminary data indicate no hematologic or non-hematologic toxicities, improved patient-reported symptoms, reduced splenomegaly, and lower inflammatory markers. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
